MicroPort Attends CHC to Promote Firehawk

Shanghai, China – 19 August, 2014 – Shanghai MicroPort Medical (Group) Co ("MicroPort") attended China Heart Congress (CHC) 2014, held from 7 August to 10 August in Beijing, to promote its star product Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®").
 
During this most influential cardiovascular congress in China, MicroPort presented Firehawk®'s safety and efficiency with an eye-catching booth, which features theme posters, amplified Firehawk® model and a seven square-meter LED screen showing introduction video of the product. Meanwhile, MicroPort shared the latest clinical data of Firehawk® in the past three years, which was positively received by participants.
 
On 8 August, MicroPort held a satellite symposium on Firehawk®'s latest development. Several renowned experts, including Professor Runlin Gao of Fuwai Hospital, President of Shanghai Ruijin Hospital Weifeng Shen and Professor Haichang Wang from Xi'an-based Xijing Hospital, were invited to host the symposium. During the event, Professor Zheng Wu of Beijing Anzhen Hospital introduced in depth five features of Firehawk®, while Bo Xu, Director of Intervention Catheter Department with Fuwai Hospital, released the latest Research & Development results of TARGET products to the audience.
 
"Firehawk® is leading the market in both design concept and clinical results. As the first coronary stent independently designed and developed by a Chinese company, Firehawk® will contribute to the academic advancement in relevant fields," said Professor Gao.